Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy before surgery shows promise for esophageal cancer patients

NCT ID NCT06764355

First seen Feb 01, 2026 · Last updated Apr 30, 2026 · Updated 10 times

Summary

This study tests a new approach for people with locally advanced esophageal cancer. Participants receive a combination of immunotherapy and chemotherapy, followed by chemoradiation, and then surgery. The goal is to see if this sequence can shrink tumors more effectively and improve outcomes. About 50 adults will take part in this phase 2 trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TOTAL NEOADJUVANT TREATMENT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Taiwan University Hospital

    RECRUITING

    Taipei, 100229, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.